Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07051252 · ClinicalTrials.gov registry record · Phase 1
A Study of HBS-201 (Pitolisant Delayed-release)
A Phase 1 study, sponsored by Harmony Biosciences Management.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT07051252 is a Phase 1 study that has completed, run by Harmony Biosciences Management. The registered enrollment target is 46 participants.
The verdict
NCT07051252, a Phase 1 study, has completed, sponsored by Harmony Biosciences Management.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the tolerability of HBS-201 when starting at a therapeutic dose in adult participants with narcolepsy.
Interventions
- DRUG HBS-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07051252
The ClinicalTrials.gov registry entry for NCT07051252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harmony Biosciences Management, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HBS-201 is the first listed.
NCT07051252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07051252 about?
NCT07051252 is a clinical study titled "A Study of HBS-201 (Pitolisant Delayed-release)". The purpose of this study is to assess the tolerability of HBS-201 when starting at a therapeutic dose in adult participants with narcolepsy.
What is the current status of trial NCT07051252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-05-21. Estimated completion is 2025-10-13.
What interventions are being tested in trial NCT07051252?
The interventions under investigation include: HBS-201 (DRUG).
Who is sponsoring clinical trial NCT07051252?
This trial is sponsored by Harmony Biosciences Management, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.